Development and validation of a nomogram for predicting immune‐related pneumonitis after sintilimab treatment
Fuente:
Wiley Open Access
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2024
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1867004193862057984 |
|---|---|
| author | Baohui Hong Rong Chen Caiyun Zheng Maobai Liu Jing Yang |
| author_facet | Baohui Hong Rong Chen Caiyun Zheng Maobai Liu Jing Yang Baohui Hong Rong Chen Caiyun Zheng Maobai Liu Jing Yang |
| collection | Wiley Open Access |
| contents | Development and validation of a nomogram for predicting immune‐related pneumonitis after sintilimab treatment Baohui Hong Rong Chen Caiyun Zheng Maobai Liu Jing Yang Cancer Medicine AbstractBackgroundImmune‐related pneumonitis is a rare and potentially fatal adverse event associated with sintilimab. We aimed to develop and validate a nomogram for predicting the risk of immune‐related pneumonitis in patients treated with sintilimab.MethodsThe least absolute shrinkage and selection operator (LASSO) regression was used to determine risk factors. Multivariable logistic regression was used to establish a prediction model. Its clinical validity was evaluated using calibration, discrimination, decision, and clinical impact curves. Internal validation was performed against the validation set and complete dataset.ResultsThe study included 632 patients; 59 were diagnosed with immune‐related pneumonitis. LASSO regression analysis identified that the risk factors for immune‐related pneumonitis were pulmonary metastases (odds ratio [OR], 4.015; 95% confidence interval [CI]: 1.725–9.340) and metastases at >3 sites (OR, 2.687; 95% CI: 1.151–6.269). The use of combined antibiotics (OR, 0.247; 95% CI: 0.083–0.738) and proton pump inhibitors (OR, 0.420; 95% CI: 0.211–0.837) were protective factors. The decision and clinical impact curves showed that the nomogram had clinical value for patients treated with sintilimab.ConclusionsWe have developed and validated a practical nomogram model of sintilimab‐associated immune‐related pneumonitis, which provides clinical value for determining the risk of immune‐related pneumonitis and facilitating the safe administration of sintilimab therapy. 10.1002/cam4.6708 http://creativecommons.org/licenses/by/4.0/ |
| doi_str_mv | 10.1002/cam4.6708 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_cam4_6708 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by/4.0/ |
| publishDate | 2024 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Development and validation of a nomogram for predicting immune‐related pneumonitis after sintilimab treatment Baohui Hong Rong Chen Caiyun Zheng Maobai Liu Jing Yang Cancer Medicine Development and validation of a nomogram for predicting immune‐related pneumonitis after sintilimab treatment Baohui Hong Rong Chen Caiyun Zheng Maobai Liu Jing Yang Cancer Medicine AbstractBackgroundImmune‐related pneumonitis is a rare and potentially fatal adverse event associated with sintilimab. We aimed to develop and validate a nomogram for predicting the risk of immune‐related pneumonitis in patients treated with sintilimab.MethodsThe least absolute shrinkage and selection operator (LASSO) regression was used to determine risk factors. Multivariable logistic regression was used to establish a prediction model. Its clinical validity was evaluated using calibration, discrimination, decision, and clinical impact curves. Internal validation was performed against the validation set and complete dataset.ResultsThe study included 632 patients; 59 were diagnosed with immune‐related pneumonitis. LASSO regression analysis identified that the risk factors for immune‐related pneumonitis were pulmonary metastases (odds ratio [OR], 4.015; 95% confidence interval [CI]: 1.725–9.340) and metastases at >3 sites (OR, 2.687; 95% CI: 1.151–6.269). The use of combined antibiotics (OR, 0.247; 95% CI: 0.083–0.738) and proton pump inhibitors (OR, 0.420; 95% CI: 0.211–0.837) were protective factors. The decision and clinical impact curves showed that the nomogram had clinical value for patients treated with sintilimab.ConclusionsWe have developed and validated a practical nomogram model of sintilimab‐associated immune‐related pneumonitis, which provides clinical value for determining the risk of immune‐related pneumonitis and facilitating the safe administration of sintilimab therapy. 10.1002/cam4.6708 http://creativecommons.org/licenses/by/4.0/ |
| title | Development and validation of a nomogram for predicting immune‐related pneumonitis after sintilimab treatment |
| topic | Cancer Medicine |
| url | https://onlinelibrary.wiley.com/doi/10.1002/cam4.6708 |